Everolimus therapy and side‑effects: A systematic review and meta‑analysis

Arena,Claudia; Bizzoca,Maria Eleonora; Caponio,Vito Carlo Alberto; Troiano,Giuseppe; Zhurakivska,Khrystyna; Leuci,Stefania; Lo Muzio,Lorenzo

doi:10.3892/ijo.2021.5234

Everolimus therapy and side‑effects: A systematic review and meta‑analysis

Authors:
- Claudia Arena
- Maria Eleonora Bizzoca
- Vito Carlo Alberto Caponio
- Giuseppe Troiano
- Khrystyna Zhurakivska
- Stefania Leuci
- Lorenzo Lo Muzio
View Affiliations

Affiliations: Department of Clinical and Experimental Medicine, University of Foggia, I-71122 Foggia, Italy, Department of Neuroscience, Reproductive and Odontostomatological Sciences, Oral Medicine Complex Unit, Federico II University of Naples, I-80138 Naples, Italy
Published online on: June 15, 2021 https://doi.org/10.3892/ijo.2021.5234
Article Number: 54

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies have focused on identifying novel targeted agents in order to reduce the undesired side‑effects of conventional chemotherapeutic agents on normal cells. However, even targeted therapies may exert certain negative effects on healthy tissues. The present systematic review was performed in order to evaluate the type and the incidence of side‑effects in patients treated with everolimus. The PubMed and Scopus databases were searched using the following free words and MESH terms: ‘everolimus’ AND ‘side‑effects’ OR ‘toxicities’ OR ‘adverse events’. A total of 912 potentially relevant studies that were screened based on the title and abstracts were identified. A total of 731 were excluded as they did not fulfil the inclusion criteria. Of the 181 remaining studies included, the adverse events reported were obtained. The primary adverse events reported were stomatitis, leukopenia, anorexia, anaemia and fatigue. The majority of the patients reported adverse events limited to grade 1 or 2. On the whole, the data presented herein confirm the findings of previous studies on the relative safety of everolimus, a targeted therapeutic agent, which differs from that of conventional chemotherapy, and highlight the potential adverse events associated with the therapeutic use of everolimus.

View Figures

View References

1	Keefe DM and Bateman EH: Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol. 9:98–109. 2011. View Article : Google Scholar : PubMed/NCBI
2	Gomez-Pinillos A and Ferrari AC: mTOR signaling pathway and mTOR inhibitors in cancer therapy. Hematol Oncol Clin North Am. 26:483–505. vii2012. View Article : Google Scholar : PubMed/NCBI
3	Meng LH and Zheng XF: Toward rapamycin analog (rapalog)-based precision cancer therapy. Acta Pharmacol Sin. 36:1163–1169. 2015. View Article : Google Scholar : PubMed/NCBI
4	Xie J, Hao Y, Zhou ZY, Qi CZ, De G and Glück S: Economic evaluations of everolimus versus other hormonal therapies in the treatment of HR+/HER2- advanced breast cancer from a US payer perspective. Clin Breast Cancer. 15:e263–e276. 2015. View Article : Google Scholar : PubMed/NCBI
5	Madeddu C, Gramignano G, Astara G, Demontis R, Sanna E, Atzeni V and Macciò A: Pathogenesis and treatment options of cancer related anemia: perspective for a targeted mechanism-based approach. Front Physiol. 9:12942018. View Article : Google Scholar : PubMed/NCBI
6	Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 366:520–529. 2012. View Article : Google Scholar
7	Chocteau-Bouju D, Chakiba C, Mignot L, Madranges N, Pierga JY, Beuzeboc P, Quenel-Tueux N, Dieras V, Bonnefoi H, Debled M, et al: Efficacy and tolerance of everolimus in 123 consecutive advanced ER positive, HER2 negative breast cancer patients. A two center retrospective study. Breast. 24:718–722. 2015. View Article : Google Scholar : PubMed/NCBI
8	Sánchez Fructuoso A, Ruiz San Millán JC, Calvo N, Rodrigo E, Moreno MA, Cotorruelo J, Conesa J, Gómez-Alamillo C, Arias M and Barrientos A: Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients. Transplant Proc. 39:2148–2150. 2007. View Article : Google Scholar : PubMed/NCBI
9	Van Belle SJ and Cocquyt V: Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol. 47:1–11. 2003. View Article : Google Scholar : PubMed/NCBI
10	Gilreath JA, Stenehjem DD and Rodgers GM: Diagnosis and treatment of cancer-related anemia. Am J Hematol. 89:203–212. 2014. View Article : Google Scholar : PubMed/NCBI
11	Bohlius J, Weingart O, Trelle S and Engert A: Cancer-related anemia and recombinant human erythropoietin - an updated overview. Nat Clin Pract Oncol. 3:152–164. 2006. View Article : Google Scholar : PubMed/NCBI
12	Nozawa M, Nonomura N, Ueda T, Nishimura K, Kanayama HO, Miki T, Nakatani T, Tomita Y, Azuma H, Yoshioka T, et al: Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice. Jpn J Clin Oncol. 43:1132–1138. 2013. View Article : Google Scholar : PubMed/NCBI
13	Gross ME, Dorff TB, Quinn DI, Diaz PM, Castellanos OO and Agus DB: Safety and efficacy of docetaxel, bevacizumab, and everolimus for castration-resistant prostate cancer (CRPC). Clin Genitourin Cancer. Jul 14–2017.Epub ahead of print. PubMed/NCBI
14	Amitani M, Asakawa A, Amitani H and Inui A: Control of food intake and muscle wasting in cachexia. Int J Biochem Cell Biol. 45:2179–2185. 2013. View Article : Google Scholar : PubMed/NCBI
15	Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, Izzedine H and Escudier B: Targeted therapies for renal cell carcinoma: Review of adverse event management strategies. J Natl Cancer Inst. 104:93–113. 2012. View Article : Google Scholar : PubMed/NCBI
16	U.S. Department of Health and Human Services: Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf. Accessed November 27, 2017.
17	Niu Q, Wang W, Li Y, Qin S, Wang Y, Wan G, Guan J and Zhu W: Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol. 11:449–456. 2011. View Article : Google Scholar : PubMed/NCBI
18	Moscetti L, Vici P, Gamucci T, Natoli C, Cortesi E, Marchetti P, Santini D, Giuliani R, Sperduti I, Mauri M, et al: Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience. Breast. 29:96–101. 2016. View Article : Google Scholar : PubMed/NCBI
19	González Barón M, Feyjóo M, Carulla Torrent J, Camps C, Escobar Y and Belda-Iniesta C: Study of the prevalence of tumour-related asthenia in Spanish cancer patients. Clin Transl Oncol. 10:351–358. 2008. View Article : Google Scholar : PubMed/NCBI
20	Moioli M, Barra F, Maramai M, Valenzano Menada M, Vellone VG, Costantini S and Ferrero S: Mucinous ovarian cancer: Current therapeutic targets, preclinical progress, and experimental drugs. Expert Opin Investig Drugs. 28:1025–1029. 2019. View Article : Google Scholar : PubMed/NCBI
21	Bajetta E, Catena L, Fazio N, Pusceddu S, Biondani P, Blanco G, Ricci S, Aieta M, Pucci F, Valente M, et al: Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study. Cancer. 120:2457–2463. 2014. View Article : Google Scholar : PubMed/NCBI
22	Besse B, Leighl N, Bennouna J, Papadimitrakopoulou VA, Blais N, Traynor AM, Soria JC, Gogov S, Miller N, Jehl V, et al: Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. Ann Oncol. 25:409–415. 2014. View Article : Google Scholar
23	Benson AB III, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, et al: Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 22:2918–2926. 2004. View Article : Google Scholar : PubMed/NCBI
24	Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, et al: Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 47:13–47. 2000. View Article : Google Scholar : PubMed/NCBI
25	Stein J and Mann J: Specialty pharmacy services for patients receiving oral medications for solid tumors. Am J Health Syst Pharm. 73:775–796. 2016. View Article : Google Scholar : PubMed/NCBI
26	Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, et al: Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol. 15:1513–1520. 2014. View Article : Google Scholar : PubMed/NCBI
27	Irvine D, Vincent L, Graydon JE, Bubela N and Thompson L: The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals. Cancer Nurs. 17:367–378. 1994. View Article : Google Scholar : PubMed/NCBI
28	Mohandas H, Jaganathan SK, Mani MP, Ayyar M and Rohini Thevi GV: Cancer-related fatigue treatment: An overview. J Cancer Res Ther. 13:916–929. 2017.PubMed/NCBI
29	Motzer RJ, Alyasova A, Ye D, Karpenko A, Li H, Alekseev B, Xie L, Kurteva G, Kowalyszyn R, Karyakin O, et al: Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). Ann Oncol. 27:441–448. 2016. View Article : Google Scholar :
30	Sarkaria JN, Galanis E, Wu W, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, Jaeckle KA and Buckner JC: North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 81:468–475. 2011. View Article : Google Scholar
31	Tian W, Yao Y, Fan G, Zhou Y, Wu M, Xu D and Deng Y: Changes in lipid profiles during and after (neo)adjuvant chemotherapy in women with early-stage breast cancer: A retrospective study. PLoS One. 14:e02218662019. View Article : Google Scholar : PubMed/NCBI
32	Capdevila J, Sevilla I, Alonso V, Antón Aparicio L, Jiménez Fonseca P, Grande E, Reina JJ, Manzano JL, Alonso Lájara JD, Barriuso J, et al: Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: A retrospective cross-sectional analysis. BMC Cancer. 15:4952015. View Article : Google Scholar : PubMed/NCBI
33	Sun JM, Kim JR, Do IG, Lee SY, Lee J, Choi YL, Ahn JS, Ahn MJ and Park K: A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer. Br J Cancer. 109:1482–1487. 2013. View Article : Google Scholar : PubMed/NCBI
34	Tobinai K, Ogura M, Maruyama D, Uchida T, Uike N, Choi I, Ishizawa K, Itoh K, Ando K, Taniwaki M, et al: Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma. Int J Hematol. 92:563–570. 2010. View Article : Google Scholar : PubMed/NCBI
35	Hwangbo Y and Lee EK: Acute hyperglycemia associated with anti-cancer medication. Endocrinol Metab (Seoul). 32:23–29. 2017. View Article : Google Scholar
36	Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R and Zinman B; American Diabetes Association; European Association for Study of Diabetes: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 32:193–203. 2009. View Article : Google Scholar :
37	Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R and Zinman B; American Diabetes Association; European Association for the Study of Diabetes: Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 52:17–30. 2009. View Article : Google Scholar
38	Mita M, Mita A and Rowinsky EK: mTOR inhibition for cancer therapy: past, present and future. Springer-Verlag; Paris: 2015
39	Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, Fischer PM, Trinos MJ, Patil S and Motzer RJ: Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 118:1868–1876. 2012. View Article : Google Scholar
40	Hassan B, Yusoff Z and Othman: A close look at neutropenia among cancer patients - risk factor and management. Updates on Cancer Treatment. IntechOpen. 2015.https://www.intechopen.com/books/updates-on-cancer-treatment/a-close-look-at-neutropenia-among-cancer-patients-risk-factor-and-management. Accessed October 28, 2015. View Article : Google Scholar
41	Ju Y, Hu Y, Sun S, Wang J and Jiao S: Toxicity and adverse effects of everolimus in the treatment of advanced nonsmall cell lung cancer pretreated with chemotherapy - Chinese experiences. Indian J Cancer. 52(Suppl 1): e32–e36. 2015. View Article : Google Scholar
42	Kanesvaran R, Watt K, Turnbull JD, Armstrong AJ, Wolkowiez MC and George DJ: A single-arm phase 1b study of everolimus and sunitinib in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 13:319–327. 2015. View Article : Google Scholar : PubMed/NCBI
43	Amato RJ, Jac J, Giessinger S, Saxena S and Willis JP: A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer. 115:2438–2446. 2009. View Article : Google Scholar : PubMed/NCBI
44	Kuter DJ: Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 29:282–284. 2015.
45	Nishino M, Brais LK, Brooks NV, Hatabu H, Kulke MH and Ramaiya NH: Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: A radiographic pattern-based approach. Eur J Cancer. 53:163–170. 2016. View Article : Google Scholar : PubMed/NCBI
46	Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ and Hricak H: CT findings of chemotherapy-induced toxicity: What radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology. 258:41–56. 2011. View Article : Google Scholar
47	Limper AH: Chemotherapy-induced lung disease. Clin Chest Med. 25:53–64. 2004. View Article : Google Scholar : PubMed/NCBI
48	Vlahovic G, Meadows KL, Uronis HE, Morse MA, Blobe GC, Riedel RF, Zafar SY, Alvarez-Secord A, Gockerman J, Starodub AN, et al: A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemother Pharmacol. 70:95–102. 2012. View Article : Google Scholar : PubMed/NCBI
49	Weisshaar E, Fleischer AB Jr, Bernhard JD, et al: Pruritus and dysesthesia. Dermatology. Bolognia JL, Jorizzo JL and Schaffer JV: Elsevier Saunders; pp. 111–125. 2012
50	Jóźwiak S, Kotulska K, Berkowitz N, Brechenmacher T and Franz DN: Safety of everolimus in patients younger than 3 years of age: results from EXIST-1, a randomized, controlled clinical trial. J Pediatr. 172:151–155.e1. 2016. View Article : Google Scholar
51	Castagnola E, Fontana V, Caviglia I, Caruso S, Faraci M, Fioredda F, Garrè ML, Moroni C, Conte M, Losurdo G, et al: A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis. 45:1296–1304. 2007. View Article : Google Scholar : PubMed/NCBI
52	Tan P, Tiong IS, Fleming S, Pomilio G, Cummings N, Droogleever M, McManus J, Schwarer A, Catalano J, Patil S, et al: The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: A phase Ib/II study. Oncotarget. 8:52269–52280. 2016. View Article : Google Scholar
53	Amato RJ, Flaherty AL and Stepankiw M: Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer. Clin Genitourin Cancer. 10:26–31. 2012. View Article : Google Scholar
54	Aapro M, Andre F, Blackwell K, Calvo E, Jahanzeb M, Papazisis K, Porta C, Pritchard K and Ravaud A: Adverse event management in patients with advanced cancer receiving oral everolimus: Focus on breast cancer. Ann Oncol. 25:763–773. 2014. View Article : Google Scholar : PubMed/NCBI
55	Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N, Huftalen T, Jederlinic N, Manola J, Wagner AJ, et al: Combination mTOR and IGF-1R inhibition: Phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 17:871–879. 2011. View Article : Google Scholar
56	Staves KL and Ramchandran KJ: Prevention and treatment options for mTOR inhibitor-associated stomatitis. JCSO. 15:74–81. 2017. View Article : Google Scholar
57	Lacouture M and Sibaud V: Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails. Am J Clin Dermatol. 19(Suppl 1): 31–39. 2018. View Article : Google Scholar : PubMed/NCBI
58	Watters AL, Epstein JB and Agulnik M: Oral complications of targeted cancer therapies: A narrative literature review. Oral Oncol. 47:441–448. 2011. View Article : Google Scholar : PubMed/NCBI
59	Raber-Durlacher JE, Elad S and Barasch A: Oral mucositis. Oral Oncol. 46:452–456. 2010. View Article : Google Scholar : PubMed/NCBI
60	Priestman T: Cancer chemotherapy in clinical practice. Springer; New York, NY: 2012, View Article : Google Scholar
61	Razmara F and Khayamzadeh M: An Investigation into the prevalence and treatment of oral mucositis after cancer treatment. Int J Cancer Manag. 12:e884052019. View Article : Google Scholar
62	Naidu MU, Ramana GV, Rani PU, Mohan IK, Suman A and Roy P: Chemotherapy-induced and/or radiation therapy-induced oral mucositis - complicating the treatment of cancer. Neoplasia. 6:423–431. 2004. View Article : Google Scholar : PubMed/NCBI